Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immunovant, Inc. IMVT
$17.92
-$0.35 (-1.97%)
На 18:02, 12 мая 2023
-72.10%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2447303550.00000000
-
week52high
20.25
-
week52low
3.15
-
Revenue
0
-
P/E TTM
-12
-
Beta
1.01933700
-
EPS
-1.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
06 июн 2023 г. в 12:30
Описание компании
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | 08 дек 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 08 ноя 2021 г. |
| Baird | Neutral | Outperform | 03 авг 2021 г. |
| SVB Leerink | Outperform | Outperform | 02 июн 2021 г. |
| HC Wainwright & Co. | Buy | 02 июн 2021 г. | |
| Chardan Capital | Buy | Buy | 29 сент 2022 г. |
| UBS | Neutral | Buy | 26 сент 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 07 ноя 2022 г. |
| Wells Fargo | Overweight | Equal-Weight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Macias William L. | D | 262996 | 537 | 02 февр 2023 г. |
| Levine Mark S. | D | 245660 | 10156 | 26 янв 2023 г. |
| Salzmann Peter | D | 993932 | 4021 | 11 янв 2023 г. |
| Barnett Eva Renee | D | 268347 | 4499 | 11 янв 2023 г. |
| Barnett Eva Renee | D | 272846 | 11 | 11 янв 2023 г. |
| Butchko Julia G. | D | 331419 | 60471 | 11 янв 2023 г. |
| Butchko Julia G. | D | 391890 | 19 | 11 янв 2023 г. |
| Macias William L. | D | 263533 | 44448 | 11 янв 2023 г. |
| Macias William L. | D | 307981 | 120 | 11 янв 2023 г. |
| Macias William L. | D | 308101 | 341 | 21 окт 2022 г. |
Новостная лента
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
24/7 Wall Street
19 янв 2023 г. в 22:53
Mid-cap stocks are proving to be an attractive investment option over the past few years.
These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022
24/7 Wall Street
09 янв 2023 г. в 22:50
Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.
Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating
Seeking Alpha
08 янв 2023 г. в 08:47
Immunovant is developing a similar drug to argenx, but at 10% of argenx's valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin levels (which was the key overhang for batoclimab).
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
Zacks Investment Research
16 дек 2022 г. в 09:47
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Are Medical Stocks Lagging Immunovant (IMVT) This Year?
Zacks Investment Research
15 дек 2022 г. в 11:17
Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.